Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07011589 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 2026 to Jan 2028
    • Start date: Jul 2025 to Jul 2026
    • Primary endpoints revised (3)
    • Study completion date: Oct 2026 to Jan 2028
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
Trial Details
NCT Number NCT07011589
Lead Sponsor M. Peter Marinkovich
Collaborators: argenx
Conditions
(from sponsor)		 Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Related terms Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Epidermolysis Bullosa Dystrophica
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov